


# Biogen Addressing Alzheimer's Disease Underserved Patient Populations (AD-UP) in Clinical Research and Health Care System Readiness




>5.5 million people in the US diagnosed with dementia due to AD

- 1 in 10 seniors is diagnosed with AD dementia
- If unaddressed, the number of cases is expected to more than double by 2050



Older African Americans are 2X as likely to have Alzheimer's disease and other dementias as older whites

## AD Patient Journey



The US health care system infrastructure for an AD disease modifying treatment faces significant challenges and capacity constraints to be overcome (Rand report 2018). Underserved AD populations will likely see greater impact

## AD – UP

**Vision**  
 To Improve patient outcomes among racial and ethnic minority populations with Alzheimer's Disease



### Strategic Framework

Clinical Research

Support data generation efforts to address unmet needs and data gaps of racial and ethnic minorities in AD

Educate

Educate to drive understanding of the specific needs of racial and ethnic minorities in AD


Collaborate

Collaborate with strategic partners to innovate solutions



### Goals / Guiding Principles

- Build Biogen Trust, Value, Engagement with Underserved Communities Globally
- Increase underserved patient population clinical research awareness and participation
- Expand publications and further studies of underserved patient populations in AD
- Proactively identify and address gaps



1. Alzheimer' Association Facts and Figures, 2020, 2. Alzheimer Assoc. Facts & Figures 2019  
 3. Liu JL et.al. Assessing the Preparedness of the US health care system for an Alzheimer treatment, Rand Corp 2018